{{Rsnum
|rsid=2069526
|Gene=CYP1A2
|Chromosome=15
|position=74749000
|Orientation=plus
|GMAF=0.06382
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=CYP1A2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 0.0 | 0.9 | 99.1
| HCB | 0.0 | 17.2 | 82.8
| JPT | 0.0 | 9.7 | 90.3
| YRI | 2.0 | 23.8 | 74.1
| ASW | 1.8 | 22.8 | 75.4
| CHB | 0.0 | 17.2 | 82.8
| CHD | 0.9 | 17.4 | 81.7
| GIH | 1.0 | 11.9 | 87.1
| LWK | 0.9 | 11.8 | 87.3
| MEX | 1.7 | 6.9 | 91.4
| MKK | 0.0 | 14.1 | 85.9
| TSI | 0.0 | 6.9 | 93.1
| HapMapRevision=28
}}[[rs2069526]] is a SNP in the [[CYP1A2]] gene.

The [[rs2069526]](T) allele defines the CYP1A2*1K_-739T>G variant.

{{PharmGKB
|RSID=rs2069526
|Name_s=CYP1A2:(-)739T>G; CYP1A2:(-)740T>G; part of CYP1A2*K; CYP1A2*1E
|Gene_s=CYP1A2
|Feature=Intron
|Evidence=PubMed ID:12920202
|Annotation=Present in reduced function haplotype, unlikely to be causative.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145041
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2069526
|overall_frequency_n=8
|overall_frequency_d=128
|overall_frequency=0.0625
|n_genomes=6
|n_genomes_annotated=0
|n_haplomes=6
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=25081684
|Title=Four Polymorphisms in the Cytochrome P450 1A2 (CYP1A2) Gene and Lung Cancer Risk: a Meta-analysis
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}